1. Prognostic factors in desmoid tumours: an example of translational oncology

   • Soledad Gallego Melcón

   Editorial 08 April 2011 Pages: 139 - 140

2. Patients, pathways, progress

   • Enrique García Jordá

   News and Views 08 April 2011 Pages: 141 - 142

3. Mechanism of hot flashes

   • Santiago Vilar-González
   • Alberto Pérez-Rozos
   • Ruben Cabanillas-Farpón

   Educational Series 08 April 2011 Pages: 143 - 147

4. Direct antitumour activity of zoledronic acid: preclinical and clinical data

   • Joaquim Bosch-Barrera
   • Sofía D. Merajver
   • Catherine Van Poznak

   Educational Series 08 April 2011 Pages: 148 - 155

5. New technologies in cancer. Protein microarrays for biomarker discovery

   • Sergio Matarraz
   • María González-González
   • Manuel Fuentes

   Educational Series 08 April 2011 Pages: 156 - 161

6. Treatment recommendations for metastatic colorectal cancer

   • Enrique Aranda
   • Albert Abad
   • Eduardo Díaz-Rubio

   Educational Series 08 April 2011 Pages: 162 - 178

7. Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer

   • Cristina Grávalos
   • Carlos Gómez-Martín
   • Antonio Jimeno

   Research Articles 08 April 2011 Pages: 179 - 184

8. Spinal cord astrocytoma: multidisciplinary experience

   • M. Isabel Tovar Martín
   • Escarlata López Ramírez
   • Mercedes Zurita Herrera

   Research Articles 08 April 2011 Pages: 185 - 188

9. Multimodal treatment of desmoid tumours: the significance of local control

   • Bella Pajares
   • Esperanza Torres
   • Emilio Alba

   Research Articles 08 April 2011 Pages: 189 - 193

10. Alternate PAX3 and PAX7 C-terminal isoforms in myogenic differentiation and sarcomagenesis

    • Elizabeth Charytonowicz
    • Igor Matushansky
    • Mel Ziman

    Research Articles 08 April 2011 Pages: 194 - 203

11. Circulating tumour cells in peripheral blood: potential impact on breast cancer outcome

    • María José Serrano
    • José Antonio Lorente
    • Pedro Sánchez Rovira

    Research Articles 08 April 2011 Pages: 204 - 208

12. Approval denied by the European Medicines Agency (EMA) for bevacizumab in the treatment of high-grade glioma recurrence: a good idea or a grave error?

    • Carmen Balañá
    • Olatz Etxaniz
    • Alex Martínez

    Correspondence 08 April 2011 Pages: 209 - 210